V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF: v-Raf murineReferences 1. Vogelstein B, Fearton ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations through colorectal-tumor development. N Engl J Med. 1998;319:5252. 2. Shimada H, Okazumi S, Takeda A, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al. Presence of serum p53 antibodies is linked with decreased in vitro chemo sensitivity in sufferers with esophageal cancer. Surg Right now. 2001;31:5916. 3. Mollevi DG, Serrano T, GinestMM, Valls J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastasis undergoing surgical resection. Carcinogenesis. 2007;28:12417. 4. Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, et al. A prospective, blinded evaluation of thymidylate synthase and p53 expression as prognostic markers within the adjuvant remedy of colorectal cancer. Annals of Oncology. 2006;17:18107. 5. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in individuals with several varieties of cancer: assay, identification, and characterization.Boc-NH-PEG11-NH2 custom synthesis Clin Cancer Res. 1995;1(12):14639. six. Blanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin V, Hennequin C, et al.Buy335654-08-5 Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.PMID:22943596 BMC Cancer. 2012;12:119. 7. Bazan V, Agnese V, Corsale S, CalV, Valerio MR, Latteri MA, et al. Distinct TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol. 2005;16:Suppl 4:505. eight. Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Study Group. Titration of serum p53 antibodies in 1085 individuals with many cancers. A multi-institutional evaluation by Japan p53 Antibody Study Group. Cancer. 2003;97:6829. 9. Fukushima Y, Yanaka S, Murakami K, et al. High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffinembedded tissue specimens of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2011;38:18255.Osumi et al. BMC Cancer (2015) 15:Web page 9 of10. Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic evaluation and concentrate on colorectal cancer. World J Gastroenterol. 2013;19(29):46510. 11. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is much more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvanttreated stage III colon cancer sufferers. J Clin Oncol. 2005;23(24):56353. 12. Angelopoulou K, Stratis M, Diamandis EP. Humoral immuneresponse against p53 protein in individuals with colorectalcarcinoma. Int J Cancer. 1997;70:461. 13. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study around the prognostic and predictive significance of p53 mutation: influence of tumor site, form of mutation, and adjuvant therapy. J Clin Oncol. 2005;23:75188. 14. Lan YT, Chang SC, Li AF, Lin TC, Chen WS, Jiang JK, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007;22(five):49906. 15. Triantafyllou K, Paspatis GA, Zizi A, Papatheodoridis GV, Tzouvala M, Chlouverakis GJ, et al. p53 protein accumulation and colonic adenoma recurrence.